| β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes AE Butler, J Janson, S Bonner-Weir, R Ritzel, RA Rizza, PC Butler Diabetes 52 (1), 102-110, 2003 | 5489 | 2003 |
| Increased risk of type 2 diabetes in Alzheimer disease J Janson, T Laedtke, JE Parisi, P O’Brien, RC Petersen, PC Butler Diabetes 53 (2), 474-481, 2004 | 1124 | 2004 |
| Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies M Elashoff, AV Matveyenko, B Gier, R Elashoff, PC Butler Gastroenterology 141 (1), 150-156, 2011 | 1014 | 2011 |
| Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers R Kayed, E Head, F Sarsoza, T Saing, CW Cotman, M Necula, L Margol, ... Molecular neurodegeneration 2, 1-11, 2007 | 870 | 2007 |
| β-cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans JJ Meier, AE Butler, Y Saisho, T Monchamp, R Galasso, A Bhushan, ... Diabetes 57 (6), 1584-1594, 2008 | 803 | 2008 |
| The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. J Janson, RH Ashley, D Harrison, S McIntyre, PC Butler Diabetes 48 (3), 491-498, 1999 | 781 | 1999 |
| Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis L Haataja, T Gurlo, CJ Huang, PC Butler Endocrine reviews 29 (3), 303-316, 2008 | 712 | 2008 |
| Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? JJ Meier, A Bhushan, AE Butler, RA Rizza, PC Butler Diabetologia 48, 2221-2228, 2005 | 639 | 2005 |
| Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action … AE Butler, J Janson, WC Soeller, PC Butler Diabetes 52 (9), 2304-2314, 2003 | 543 | 2003 |
| Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy AE Butler, L Cao-Minh, R Galasso, RA Rizza, A Corradin, C Cobelli, ... Diabetologia 53, 2167-2176, 2010 | 532 | 2010 |
| Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type‐2 diabetes Y Saisho, AE Butler, JJ Meier, T Monchamp, M Allen‐Auerbach, RA Rizza, ... Clinical anatomy 20 (8), 933-942, 2007 | 522 | 2007 |
| High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress–mediated β-cell apoptosis, a characteristic of humans with type 2 but not type 1 … C Huang, C Lin, L Haataja, T Gurlo, AE Butler, RA Rizza, PC Butler Diabetes 56 (8), 2016-2027, 2007 | 495 | 2007 |
| Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing … AE Butler, M Campbell-Thompson, T Gurlo, DW Dawson, M Atkinson, ... Diabetes 62 (7), 2595-2604, 2013 | 492 | 2013 |
| β-cell mass and turnover in humans: effects of obesity and aging Y Saisho, AE Butler, E Manesso, D Elashoff, RA Rizza, PC Butler Diabetes care 36 (1), 111-117, 2013 | 430 | 2013 |
| Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. J Janson, WC Soeller, PC Roche, RT Nelson, AJ Torchia, DK Kreutter, ... Proceedings of the National Academy of Sciences 93 (14), 7283-7288, 1996 | 424 | 1996 |
| Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans PC Butler, J Chou, WB Carter, YN Wang, BH Bu, D Chang, JK Chang, ... Diabetes 39 (6), 752-756, 1990 | 416 | 1990 |
| Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests C Cobelli, GM Toffolo, CD Man, M Campioni, P Denti, A Caumo, P Butler, ... American Journal of Physiology-Endocrinology and Metabolism 293 (1), E1-E15, 2007 | 395 | 2007 |
| The replication of β cells in normal physiology, in disease and for therapy PC Butler, JJ Meier, AE Butler, A Bhushan Nature clinical practice Endocrinology & metabolism 3 (11), 758-768, 2007 | 367 | 2007 |
| A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? PC Butler, M Elashoff, R Elashoff, EAM Gale Diabetes care 36 (7), 2118-2125, 2013 | 353 | 2013 |
| Type 2 diabetes as a protein misfolding disease A Mukherjee, D Morales-Scheihing, PC Butler, C Soto Trends in molecular medicine 21 (7), 439-449, 2015 | 349 | 2015 |
